GLG News by Users of Dermal Fillers (US)

This article is important in that this acquisition is the first new product for Allergan's dermatology division in several years. This is also the first novel molecule in 5-7 years that has been released. The issues of having to get blood tests with this topical agent have been solved. The obvious paring...

- Dark circles underneath the eyes give the unappealing impression of exhaustion. Many factors, both hereditary and environmental, can produce or exacerbate this condition.  - Despite efforts to address this unmet need, the over-the-counter cosmetic industry has not been able to address consumer's...

How can safety be verified with the Chinese history of contaminants in the toy and food industries.  I certainly would not want to take Chinese drugs. lynn tucker

This article is important in that it is a good summary of the current knowledge and treatment methods for atopic dermatitis for pediatricians. It is needed in that this condition is inadequately treated, and a periodic refresher is needed for all physicians. Both pharmacologic and non pharmacologic...

This article is important in that it makes the public aware that they should avoid all unlicensed persons who re injecting any substance into their bodies. These especially include those injecting silicone mixtures. The public will become more aware and should have more confidence in licensed practitioners...

 This article is important in that it lays to rest a misconception that long term repeated use of Botox ( Allergan) leads to decreased efficacy. Efficacy was maintained, and no neutralizing antibodies were found to Botox. This will reassure most users of Botox, and patients as well.

 This article is important in that it defined the incidence of serious skin reactions to the three common TNF antagonists- Enbrel, Humira, and Remicade. The incidence is relatively low in comparison to the numbers of patients treated. Any foreign protein has the potential for eliciting these reactions,...

Anacor's recent release of the data from their phase 2a study of AN 2728  for psoriasis were encouraging.  Over 69% actively treated plaques of psoriasis improved versus only 6% of placebo treated plaques. The study was limited by the short duration- only 28 days versus up to 16...

 This article is important in that it is one of the first to confirm what is  a widely held belief among many dematologists who treat many patients with psoriasis. Specifically that these patients suffer a higher rate of cardiovascular diseases, depression, malignancy, etc. This makes perfect...

Centocors new product- Ustekinumab /CNTO 1275 had impressive results in the recent PHOENIX trials and the application is under review at the FDA. The PASI score reductions are superior to the exiting agents such as Enbrel and Humira, and are comparable to those of the other Centocor product- Remicade...